We are live on ! Find out more
RVMD icon

Revolution Medicines

172.29 USD
-4.06
2.3%
At close Updated Nov 13, 4:00 PM EST
Pre-market
After hours
169.91
-2.38
1.38%
1 day
-2.3%
5 days
-11.89%
1 month
-8.57%
3 months
-14.71%
6 months
14.91%
Year to date
118.03%
1 year
167.61%
5 years
442.13%
10 years
496.16%
 

About: Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Employees: 883

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 64%
Neutral 34%
Negative 2%
Positive
Seeking Alpha
3 days ago
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over 5,000 unique U.S. patients and broad reimbursement, but initial revenues include non-recurring factors and should not be annualized. RVMD's valuation is demanding at 63x forward sales, reflecting high expectations for RASONQUE's expansion and pipeline execution, leaving little room for operational missteps.
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
Neutral
Seeking Alpha
5 days ago
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO.
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
Positive
The Motley Fool
7 days ago
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Positive
The Motley Fool
7 days ago
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Positive
Seeking Alpha
10 days ago
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained commercial traction or pivotal readouts materialize. RASONQUE's clinical data show clear superiority over chemotherapy in pancreatic cancer; expansion into NSCLC and other solid tumors underpins RVMD's multi-asset pipeline thesis.
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
Positive
Zacks Investment Research
10 days ago
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
Revolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
Positive
Market Watch
10 days ago
This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time'
Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time'
Neutral
Investors Business Daily
10 days ago
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Neutral
MarketBeat
11 days ago
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
Price charts implemented using Lightweight Charts™